中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2015年
7期
621-623
,共3页
依达拉奉%胞二磷胆碱%急性脑梗死
依達拉奉%胞二燐膽堿%急性腦梗死
의체랍봉%포이린담감%급성뇌경사
Edaravone%Citicoline%Acute ischemic cerebral infarction
目的 观察依达拉奉联合胞二磷胆碱治疗急性脑梗死的临床效果.方法 选取2012年3月至2013年8月在我院治疗的82例急性脑梗死患者进行单盲法研究,按照入院先后顺序分为干预组和对照组,每组各41例.对照组在常规治疗方法基础上给予奥扎格雷钠80 mg,2次/d,静脉滴注,连续14d.干预组应用依达拉奉30 mg,2次/d,静脉滴注,连续14 d;外加胞二磷胆碱1 000mg,静脉滴注,连续14 d.对比观察两组的治疗效果.结果 干预组治疗前、后神经功能缺损(NIHSS)评分分别为(14.1±3.2)分、(5.1±1.6)分、日常生活能力(Barthel)指数分别为(51.6±13.5)、(73.1±15.9)、血清超氧化物歧化酶(SOD)分别为(145.3±32.6) U/L、(226.9±39.7)U/L,对照组治疗前后NIHSS评分分别为(13.7±3.3)分、(10.2±3.0)分、Barthel指数分别为53.4±13.8、59.9±14.1、血清SOD浓度分别为(143.6±33.8) U/L、(179.4±35.7) U/L,两组治疗后均较治疗前有显著改善,差异有统计学意义(干预组:t值分别为16.108、6.600、10.171,P均＜0.01,对照组:t值分别为5.025、2.110、4.663,P均＜0.05或P＜0.01),且干预组治疗后与对照组比较差异有统计学意义(t值分别为0.605,3.977,5.697,P均＜0.01).干预组总有效率97.6％(40/41)显著高于对照组80.5％(33/41),差异有统计学意义(x2=4.49,P＜0.05).结论 依达拉奉联合胞二磷胆碱治疗急性脑梗死效果良好,可以有效地保护脑组织,改善患者神经功能缺损,提高日常生活能力.
目的 觀察依達拉奉聯閤胞二燐膽堿治療急性腦梗死的臨床效果.方法 選取2012年3月至2013年8月在我院治療的82例急性腦梗死患者進行單盲法研究,按照入院先後順序分為榦預組和對照組,每組各41例.對照組在常規治療方法基礎上給予奧扎格雷鈉80 mg,2次/d,靜脈滴註,連續14d.榦預組應用依達拉奉30 mg,2次/d,靜脈滴註,連續14 d;外加胞二燐膽堿1 000mg,靜脈滴註,連續14 d.對比觀察兩組的治療效果.結果 榦預組治療前、後神經功能缺損(NIHSS)評分分彆為(14.1±3.2)分、(5.1±1.6)分、日常生活能力(Barthel)指數分彆為(51.6±13.5)、(73.1±15.9)、血清超氧化物歧化酶(SOD)分彆為(145.3±32.6) U/L、(226.9±39.7)U/L,對照組治療前後NIHSS評分分彆為(13.7±3.3)分、(10.2±3.0)分、Barthel指數分彆為53.4±13.8、59.9±14.1、血清SOD濃度分彆為(143.6±33.8) U/L、(179.4±35.7) U/L,兩組治療後均較治療前有顯著改善,差異有統計學意義(榦預組:t值分彆為16.108、6.600、10.171,P均＜0.01,對照組:t值分彆為5.025、2.110、4.663,P均＜0.05或P＜0.01),且榦預組治療後與對照組比較差異有統計學意義(t值分彆為0.605,3.977,5.697,P均＜0.01).榦預組總有效率97.6％(40/41)顯著高于對照組80.5％(33/41),差異有統計學意義(x2=4.49,P＜0.05).結論 依達拉奉聯閤胞二燐膽堿治療急性腦梗死效果良好,可以有效地保護腦組織,改善患者神經功能缺損,提高日常生活能力.
목적 관찰의체랍봉연합포이린담감치료급성뇌경사적림상효과.방법 선취2012년3월지2013년8월재아원치료적82례급성뇌경사환자진행단맹법연구,안조입원선후순서분위간예조화대조조,매조각41례.대조조재상규치료방법기출상급여오찰격뢰납80 mg,2차/d,정맥적주,련속14d.간예조응용의체랍봉30 mg,2차/d,정맥적주,련속14 d;외가포이린담감1 000mg,정맥적주,련속14 d.대비관찰량조적치료효과.결과 간예조치료전、후신경공능결손(NIHSS)평분분별위(14.1±3.2)분、(5.1±1.6)분、일상생활능력(Barthel)지수분별위(51.6±13.5)、(73.1±15.9)、혈청초양화물기화매(SOD)분별위(145.3±32.6) U/L、(226.9±39.7)U/L,대조조치료전후NIHSS평분분별위(13.7±3.3)분、(10.2±3.0)분、Barthel지수분별위53.4±13.8、59.9±14.1、혈청SOD농도분별위(143.6±33.8) U/L、(179.4±35.7) U/L,량조치료후균교치료전유현저개선,차이유통계학의의(간예조:t치분별위16.108、6.600、10.171,P균＜0.01,대조조:t치분별위5.025、2.110、4.663,P균＜0.05혹P＜0.01),차간예조치료후여대조조비교차이유통계학의의(t치분별위0.605,3.977,5.697,P균＜0.01).간예조총유효솔97.6％(40/41)현저고우대조조80.5％(33/41),차이유통계학의의(x2=4.49,P＜0.05).결론 의체랍봉연합포이린담감치료급성뇌경사효과량호,가이유효지보호뇌조직,개선환자신경공능결손,제고일상생활능력.
Objective To observe the clinical effect of edaravone combined with citicoline for treatment of acute ischemic cerebral infarctio.Methods Eighty-two cases patients of acute cerebral infarction were selected from March 2012 to August 2013 in the General Hospital of XingTai Mining group.According to admission order,they were randomly divided into observation group and control group,and each group of 41 cases.Single blind studies were carried out and on the basis of conventional treatment methods,the control group was given ozagrel sodium 80 mg,2 times/d,continuous 14 days.Observation group applied 30 mg edaravone,2 times/d,continuous 14 days.Besides this,observation group were given citicoline 1 000 mg,ontinuous 14 days.Comparison of therapeutic effects were observed for 14 days.Results Before and after treatment,the national institutes of health stroke scale (NIHSS) score,Barthel index,superoxide dismutase (SOD) of observation group were (14.1±3.2) and (5.1±1.6),(51.6±13.5) and (73.1±15.9),(145.3±32.6) U/L and (226.9± 39.7) U/L,which of control group were (13.7 ± 3.3) and (10.2± 3.0),(53.4± 13.8) and (59.9±14.1),(143.6±33.8) U/L and (179.4±35.7) U/L,and there were significant difference between before and after treatment of two groups(observation group:t=16.108,6.600,10.171,P＜0.01;control group:t =5.025,2.110,4.663,P＜0.05),and between observation group and control group after treatment(t =0.605,3.977,5.697,P＜0.01).Furthermore observation group's total effective rate was 97.6％ (40/41),significantly better than that of control group,and the difference was significant (80.5％ (33/41),x2 =4.49,P ＜0.05).Conclusion It is better that edaravone combined with citicoline for the treatment of acute ischemic cerebral infarction which can effectively protect the brain tissue,improve the patients' neurologic deficits and their ability of daily life.
